A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Primary Objective
To compare efficacy between Arm A (sonrotoclax plus zanubrutinib [SZ]) versus Arm B (venetoclax plus obinutuzumab [VO]), as measured by progression-free survival (PFS) determined by the independent review committee (IRC).
![](https://researchstudies.cuanschutz.edu/Content/images/study-category-images/cancer.jpg)
Details
Age
Adult
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
![Photograph of MANALI KAMDAR](https://som.ucdenver.edu/FIMS/Content/faculty/22517/CU-Doctors-22517.jpg)
MANALI KAMDAR
Study ID
Protocol Number: 23-1756
More information available at ClinicalTrials.gov: NCT06073821
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers